August 2010 Volume 6, Issue 8
Volume 6, Issue 8 | August 2010
August 2010
In this Issue
Global News
A pain-free alliance
Servier and Galapagos initiate strategic alliance in osteoarthritisThat’s Italian
Aptuit to acquire operations at GSK’s Medicines Research Centre in VeronaThe potential of Polish science
Selvita and Orion collaborate on Alzheimer’s disease programFrom the Buckeye State to Beijing
BioOhio, Beijing Pharma forge international biomedical, business partnershipCommentary
The role of nanoemulsions in vaccines, adjuvants, anti-infectives and dermatological treatments
The pharmaceutical industry continues to struggle with bringing new, commercially viable therapies to market.Where will innovation come from?
In the early 1980s, I traveled to Berlin and to China for the first time. To reach Berlin, you flew in a PanAm DC-9 from Frankfurt, your only choice of airline and departure airport. It was a beautiful day. Crossing the border to East Germany, many things disappeared: color, highways, modern buildings and traffic. From low altitudes, it appeared that 30 to 40 years had just been lost.Editor's Focus
ddn dissects current cancer craze
Business deals and agreements associated with cancer research are plentiful these days, and this month, ddn’s editors and writers give you several examples of the latest oncology-related acquisitions, mergers and partnerships to be signed in this burgeoning area of pharmaceutical and biological research.Research & Development
Celgene reaches into deep pockets again
Enticed by tumor drug, Celgene acquires Abraxis BioScience for nearly $3 billion upfront and up to $650 million if certain goals are metGetting under their skin
Valeant and Biovail agree to merge, creating leader in dermatology and neurology pharmaceuticalssanofi-aventis continues R&D spending spree
French pharma acquires U.S. biopharmaceutical firm TargeGen for $75 millionLilly acquisition blossoms
Company to pay as much as $380 million for AlnaraFail-safe product and deal
Option agreement between Cadence Pharmaceuticals and Incline Therapeutics gives Cadence two option periods to acquire InclineInstruments & Informatics
Human genomics for the masses
Roche and IBM collaborate on nanopore-based DNA sequencing technology with eyes toward advancing personalized healthcareSosei to acquire Activus Pharma
Deal marks Sosei’s continued efforts to grow through non-organic meansPicking up the slack … and then some
Eurofins MWG Operon and Genomatix join forces to offer advanced NGSGetting a signal
Promega, SignalChem to offer complete kinase solutionsOmics & Systems Biology
Multimillion miRNA deal
sanofi-aventis, Regulus form strategic alliance in microRNA therapeuticsBoosting R&D with a little M&A
Gilead Sciences acquires CGI Pharmaceuticals and adds numerous small- molecule kinase inhibitor compounds to its pipelineA class of their own
Santaris Pharma, miRagen Therapeutics to develop microRNAs for treatment of cardiovascular diseasePushing the limits of phosphoproteomics
Purdue University researcher patents new retrieval method that makes studying cancer proteins easierAriadne’s thread of connections
Bioinformatics company to collaborate in multimillion-dollar EU-based neuromuscular disease consortium to find biomarkersContract Services
Back to the future with Parkinson’s research
Michael J. Fox Foundation partners with leading CROs to develop biomarker candidates for Parkinson’s diseaseChanging the channel
Milestone-driver collaboration between Essen BioScience and Nycomed boosts ion-channel drug discoveryA gem of a partnership
Emerald BioStructures, FORMA Therapeutics partner to develop treatments for lymphoma and other cancersGoing for prime time
Quintiles inks deal with University Malaya Medical Center in MalaysiaDiagnostics
TRANSCENDing a typical partnership
MIT’s Koch Institute collaborates with Ortho-McNeil-Janssen and affiliates in oncology R&DA personal touch for cancer therapy
Aeterna Zentaris to collaborate with Almac on therapy and companion diagnostic in multiple oncology targetsSigned on the dotted line
Signature Diagnostics to use Affymetrix microarray technology for detecting and predicting progression of colorectal cancerRheumatoid arthritis reprise
TcLand Expression, a spinoff of Inserm Transfert, rejoins former partner to pursue RA companion diagnosticsSpecial Reports
Let’s work together
Peeling back the layers of integrated approaches to oncology researchThe big picture
Multiple approaches—and ultimately, more comprehensive ones—are critical to understanding and treating cancerNew Products
